4//SEC Filing
EDELMAN JOSEPH 4
Accession 0001193125-25-280481
CIK 0001327273other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 5:07 PM ET
Size
20.5 KB
Accession
0001193125-25-280481
Insider Transaction Report
Form 4
PERCEPTIVE ADVISORS LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-11$4.31/sh−4,783$20,637→ 161,318 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-11$4.31/sh−537$2,317→ 18,122 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−7,862$31,915→ 153,456 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−883$3,584→ 17,239 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−28,597$111,531→ 124,859 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−3,213$12,531→ 14,026 total(indirect: See Footnotes)
Transactions
- Sale
Common Stock
2025-11-11$4.31/sh−4,783$20,637→ 161,318 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-11$4.31/sh−537$2,317→ 18,122 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−7,862$31,915→ 153,456 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−28,597$111,531→ 124,859 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−883$3,584→ 17,239 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−3,213$12,531→ 14,026 total(indirect: See Footnotes)
Perceptive LS (A), LLC
10% Owner
Transactions
- Sale
Common Stock
2025-11-11$4.31/sh−4,783$20,637→ 161,318 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−7,862$31,915→ 153,456 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−28,597$111,531→ 124,859 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-11$4.31/sh−537$2,317→ 18,122 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−883$3,584→ 17,239 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−3,213$12,531→ 14,026 total(indirect: See Footnotes)
EDELMAN JOSEPH
10% Owner
Transactions
- Sale
Common Stock
2025-11-12$4.06/sh−7,862$31,915→ 153,456 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-12$4.06/sh−883$3,584→ 17,239 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-11$4.31/sh−4,783$20,637→ 161,318 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-11$4.31/sh−537$2,317→ 18,122 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−28,597$111,531→ 124,859 total(indirect: See Footnotes) - Sale
Common Stock
2025-11-13$3.90/sh−3,213$12,531→ 14,026 total(indirect: See Footnotes)
Footnotes (6)
- [F1]The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.61 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
- [F2]Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F3]The securities reported in this row are held by the Master Fund.
- [F4]The securities reported in this row are held by Perceptive LS.
- [F5]The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.27 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
- [F6]The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.91 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
Documents
Issuer
Lyra Therapeutics, Inc.
CIK 0001327273
Entity typeother
Related Parties
1- filerCIK 0001164426
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 5:07 PM ET
- Size
- 20.5 KB